Lilly raises US list prices for Mounjaro and Zepbound while cash prices fall

Eli Lilly's own pricing pages, updated as of January 1, 2026, show a wide split between the sticker price of its weight-loss and diabetes injections and what many patients actually pay out of pocket ^[1][2].

For Zepbound (tirzepatide), the list price — also called the wholesale acquisition cost, or WAC — runs from $499 to $1,086.37 per fill, based on data from AnalySource accessed that day ^[1]. But patients who pay cash directly to Lilly, outside insurance, can get the drug for far less: $299 for the 2.5 mg dose, $399 for 5 mg, $499 for 7.5 mg, and $699 for the 10 mg, 12.5 mg, and 15 mg doses, sold as vials or single-use KwikPens ^[1]. Commercially insured patients with coverage for Zepbound may pay as little as $25 for a one- or three-month supply through a savings card, though that program excludes government beneficiaries such as those on Medicare or Medicaid and comes with monthly and annual limits ^[1].

For Mounjaro (tirzepatide), Lilly's page lists the price at $1,112.16 per fill, with one fill defined as four pens, or a month's supply ^[2]. Lilly says it does not yet have data on what patients typically pay after insurance and has committed to sharing average out-of-pocket costs once available ^[2]. Commercially insured patients may qualify for the Mounjaro Savings Card, but that program excludes people on Medicaid, Medicare, Medigap, the Department of Defense, VA, TRICARE/CHAMPUS, or any state assistance program ^[2]. Uninsured patients or those whose insurance doesn't cover Mounjaro are directed to a separate Lilly self-pay page, though the pricing pages reviewed here do not list specific self-pay dollar amounts for Mounjaro the way they do for Zepbound ^[2].

Lilly's pages do not show what these list or cash prices were before January 1, 2026, so the exact size of any recent increase or decrease is not stated in this source material. What is confirmed is the current snapshot: Mounjaro's list price sits above $1,100 per month, Zepbound's list price tops out just below that, and Zepbound's direct-to-patient cash price for lower doses starts under $300 ^[1][2].

Why it matters for patients

The list price, or WAC, is what Lilly charges wholesalers — not what most patients pay at the pharmacy counter ^[1][2]. That number matters mainly for people without insurance coverage, for insurers negotiating rebates, and for calculating coinsurance percentages tied to a drug's sticker price. It is largely disconnected from what someone with commercial insurance and a savings card pays, and it does not reflect Lilly's self-pay cash program for Zepbound, which is priced well below WAC ^[1].

This explains why a patient might see a $1,086 charge referenced somewhere and then pay $299 at pickup: they are looking at two different numbers that serve two different purposes ^[1]. Coverage still varies by plan, dose, and whether a patient qualifies for savings cards, and Lilly explicitly says the most accurate answer for any individual comes from their own insurer ^[1][2].

What happens next

Lilly has said it will publish average patient out-of-pocket costs for Mounjaro once that data becomes available, though no date is given ^[2]. Both pricing pages note that list prices are pulled from AnalySource data as accessed on January 1, 2026, meaning these figures could be updated again without a specific announced schedule ^[1][2].